Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) have earned a consensus recommendation of “Buy” from the six brokerages that are covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $23.80.
Separately, Royal Bank of Canada restated an “outperform” rating and issued a $24.00 target price on shares of Lexeo Therapeutics in a research note on Tuesday, January 21st.
Check Out Our Latest Analysis on Lexeo Therapeutics
Lexeo Therapeutics Price Performance
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of LXEO. Allostery Investments LP purchased a new position in shares of Lexeo Therapeutics during the 4th quarter worth approximately $33,000. BNP Paribas Financial Markets boosted its position in shares of Lexeo Therapeutics by 184.2% during the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in shares of Lexeo Therapeutics during the fourth quarter worth $46,000. JPMorgan Chase & Co. lifted its stake in Lexeo Therapeutics by 135.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock worth $93,000 after acquiring an additional 5,915 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD acquired a new position in Lexeo Therapeutics in the 4th quarter valued at about $69,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.
Lexeo Therapeutics Company Profile
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
Recommended Stories
- Five stocks we like better than Lexeo Therapeutics
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- What is a Dividend King?
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- The Most Important Warren Buffett Stock for Investors: His Own
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.